Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CTXR

Citius Pharmaceuticals Inc

Dec 10 • 04:00PM ET

3.27

Dollar change -0.05
Percentage change -1.51	%

Healthcare • Biotechnology • USA • NASD

Peers: EBS GERN ADMA XOMA ANIP PTGX SCYX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.11	Insider Own	6.82%	Shs Outstand	7.23M	Perf Week	-7.89%
Market Cap	25.27M	Forward P/E	0.51	EPS next Y	6.44	Insider Trans	0.00%	Shs Float	7.20M	Perf Month	-68.21%
Income	-39.77M	PEG	-	EPS next Q	-1.36	Inst Own	12.24%	Short Float	7.47%	Perf Quarter	-75.32%
Sales	0.00M	P/S	-	EPS this Y	87.79%	Inst Trans	-	Short Ratio	2.49	Perf Half Y	-79.63%
Book/sh	11.85	P/B	0.28	EPS next Y	1037.86%	ROA	-36.91%	Short Interest	0.54M	Perf Year	-84.69%
Cash/sh	2.32	P/C	1.41	EPS next 5Y	-	ROE	-41.76%	52W Range	2.55 - 26.75	Perf YTD	-82.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.21%	ROI	-46.36%	52W High	-87.78%	Beta	1.36
Dividend TTM	-	Quick Ratio	6.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	28.24%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	6.75	EPS Y/Y TTM	-18.38%	Oper. Margin	-	RSI (14)	31.22	Volatility	10.45% 25.54%
Employees	22	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	150.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-13.66%	Payout	-	Rel Volume	0.31	Prev Close	3.32
Sales Surprise	-	EPS Surprise	1.75%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	215.90K	Price	3.27
SMA20	-31.60%	SMA50	-57.90%	SMA200	-78.42%	Trades		Volume	67,877	Change	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-30-21	Initiated	Maxim Group	Buy	$4

Nov-25-24 08:03AM	Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval (PR Newswire)
Nov-22-24 09:00AM	Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split (PR Newswire) -18.96%
Nov-18-24 04:05PM	Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering (PR Newswire) +12.10% -14.45%
Nov-15-24 01:30PM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering (PR Newswire) -39.10%
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +9.16%
04:30PM	Loading…
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)
Aug-13-24 09:30AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -11.69%
04:32AM	Citius merges oncology subsidiary with TenX Keane (Pharmaceutical Technology)
Aug-12-24 10:53PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 (InvestorPlace) -11.38%
05:28PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
04:22PM	Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. (PR Newswire)
08:00AM	Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments (PR Newswire)
Aug-09-24 07:30AM	TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update (GlobeNewswire) -12.36%
Aug-08-24 05:41PM	Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection (Benzinga)
06:59AM	Loading…
06:59AM	Citius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-05-24 08:00AM	TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals (GlobeNewswire)
08:00AM	Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. (PR Newswire)
Jul-18-24 07:00AM	Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL) (Newsfile)
Jul-17-24 08:00AM	Analysts Hunt for Undervalued Biotech Stocks (Newsfile)
Jul-11-24 11:00AM	Bloodstream Infections - From Threats to Solutions (Newsfile)
08:00AM	Biopharma Stocks Transformative Innovation for the Future of Health (Newsfile)
Jul-10-24 09:10AM	Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates (PR Newswire) +10.29%
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-29-24 08:30AM	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-21-24 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.64%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
10:55PM	Loading…
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace) -9.15%
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%
08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
Apr-11-24 08:30AM	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma (PR Newswire)
Apr-04-24 08:30AM	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference (PR Newswire)
Mar-18-24 08:30AM	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-07-24 08:30AM	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program (PR Newswire)
Feb-26-24 07:30AM	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration (PR Newswire)
Feb-23-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences (PR Newswire)
Feb-15-24 09:17AM	Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials (GuruFocus.com) +9.12%
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire) +13.51%
08:01AM	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jan-23-24 08:30AM	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors (PR Newswire)
Jan-02-24 08:31AM	Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters (PR Newswire) +6.90%
08:30AM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 08:30AM	Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 (PR Newswire)
Oct-31-23 08:45AM	Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor (PR Newswire)
Oct-24-23 07:30AM	Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire) +17.36%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:30PM	Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 (PR Newswire)
Sep-13-23 04:30PM	Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir (PR Newswire) -6.48%
Sep-08-23 08:00AM	Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR (PR Newswire)
Sep-06-23 04:30PM	Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 (PR Newswire) -5.25%
Aug-14-23 04:15PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -6.66%
Aug-10-23 08:37AM	Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial (PR Newswire) +8.20%
Jul-29-23 04:16PM	Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jun-26-23 08:30AM	Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes (PR Newswire) +5.43%
Jun-20-23 04:09PM	Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In Symptoms (Benzinga)
08:30AM	Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids (PR Newswire)
Jun-13-23 08:30AM	Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 (PR Newswire)
May-12-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire) +6.82% -9.22%
May-08-23 01:42PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire)
May-04-23 08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire) -16.11%
Apr-24-23 09:10AM	Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date (PR Newswire)
Apr-03-23 08:00AM	Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire) +14.53%
Mar-30-23 08:30AM	Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company (PR Newswire) +6.36%
Mar-27-23 09:52AM	When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? (Simply Wall St.)
Mar-13-23 09:15AM	Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank (PR Newswire) -5.61%
Mar-08-23 08:30AM	Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference (PR Newswire)
Feb-10-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -9.29%
Feb-06-23 10:30AM	Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks (TheStreet.com)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-16-23 07:09AM	Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation (Simply Wall St.)
Jan-11-23 08:30AM	Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 (PR Newswire) +7.10%
Dec-28-22 09:35AM	After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR) (Zacks)
Dec-22-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update (PR Newswire) -18.02%
Dec-01-22 07:30AM	Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire) +5.13%
Nov-21-22 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program (PR Newswire)
Nov-09-22 08:30AM	Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Oct-18-22 08:30AM	Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 (PR Newswire)
07:59AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook (Simply Wall St.)
Oct-06-22 04:30PM	Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 (PR Newswire)
Sep-28-22 08:30AM	Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire)
Sep-23-22 06:48AM	Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings (Benzinga)
Sep-22-22 04:30PM	Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial (PR Newswire)
Sep-15-22 08:30AM	Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute (PR Newswire)
Sep-08-22 04:30PM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) +6.40%
Sep-07-22 08:30AM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-11-22 04:31PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire) +13.33%
Aug-09-22 07:24AM	Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely (Simply Wall St.) -7.77%
Jul-12-22 08:07AM	Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
May-25-22 10:13AM	Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm (Benzinga)
08:47AM	Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company (PR Newswire)
May-18-22 09:30AM	Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 (PR Newswire)
May-12-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holuka Eugene Myron	Director	Mar 13 '24	Option Exercise	0.01	2,415	36	2,415	Aug 30 04:01 PM
Webb Carol	Director	Mar 04 '24	Option Exercise	0.01	12,071	181	12,071	Aug 30 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your FINVIZ experience